All In Biotech

Drug Trial Radar · NCT00277914

Flibanserin Randomized Withdrawal Trial in Pre-menopausal Women

12-month Sustained Efficacy of Flibanserin v Placebo n Younger Women With HSDD in NA

Last checked: Nov 20, 2026Latest source record: Mar 16, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

749

Actual

Start

Jan 2006

Primary completion

Jul 2007

Sponsor

Lead sponsor
Sprout Pharmaceuticals, IncIndustry
Sponsor type
Industry
First posted
Jan 18, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
Female only, from 18 years, up to 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To estimate the duration of efficacy with continued treatment of double-blind flibanserin or placebo over twenty-four weeks of treatment.

Conditions

  • Sexual Dysfunctions, Psychological

Interventions

  • FlibanserinDrug

    flibanserin flexible dosing

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Duration of efficacy of flibanserin in Sexually Satisfying EventsTime frame: 24 weeks

Locations

65 sites in 2 countries. Site status is shown where the registry gives one.

  • 511.74.01051 Boehringer Ingelheim Investigational Site

    Birmingham, Alabama

  • 511.74.01027 Boehringer Ingelheim Investigational Site

    Mobile, Alabama

  • 511.74.01029 Boehringer Ingelheim Investigational Site

    Scottsdale, Arizona

  • 511.74.01031 Boehringer Ingelheim Investigational Site

    Tucson, Arizona

  • 511.74.01004 Boehringer Ingelheim Investigational Site

    Jonesboro, Arkansas

  • 511.74.01053 Boehringer Ingelheim Investigational Site

    Little Rock, Arkansas

  • 511.74.01033 Boehringer Ingelheim Investigational Site

    Palm Springs, California

  • 511.74.01003 Boehringer Ingelheim Investigational Site

    Palo Alto, California

  • 511.74.01015 Boehringer Ingelheim Investigational Site

    Sacramento, California

  • 511.74.01013 Boehringer Ingelheim Investigational Site

    San Diego, California

  • 511.74.01052 Boehringer Ingelheim Investigational Site

    Torrance, California

  • 511.74.01022 Boehringer Ingelheim Investigational Site

    Aurora, Colorado

  • 511.74.01046 Boehringer Ingelheim Investigational Site

    Denver, Colorado

  • 511.74.01002 Boehringer Ingelheim Investigational Site

    Groton, Connecticut

  • 511.74.01023 Boehringer Ingelheim Investigational Site

    Middlebury, Connecticut

  • 511.74.01009 Boehringer Ingelheim Investigational Site

    West Hartford, Connecticut

  • 511.74.01035 Boehringer Ingelheim Investigational Site

    Newark, Delaware

  • 511.74.01039 Boehringer Ingelheim Investigational Site

    Coral Gables, Florida

  • 511.74.01019 Boehringer Ingelheim Investigational Site

    Gainesville, Florida

  • 511.74.01044 Boehringer Ingelheim Investigational Site

    Hollywood, Florida

  • 511.74.01001 Boehringer Ingelheim Investigational Site

    Hudson, Florida

  • 511.74.01043 Boehringer Ingelheim Investigational Site

    Pembroke Pines, Florida

  • 511.74.01032 Boehringer Ingelheim Investigational Site

    St. Petersburg, Florida

  • 511.74.01036 Boehringer Ingelheim Investigational Site

    Roswell, Georgia

  • 511.74.01047 Boehringer Ingelheim Investigational Site

    Champaign, Illinois

  • 511.74.01038 Boehringer Ingelheim Investigational Site

    Evansville, Indiana

  • 511.74.01014 Boehringer Ingelheim Investigational Site

    Lexington, Kentucky

  • 511.74.01007 Boehringer Ingelheim Investigational Site

    Baton Rouge, Louisiana

  • 511.74.01024 Boehringer Ingelheim Investigational Site

    Rockland, Maine

  • 511.74.01030 Boehringer Ingelheim Investigational Site

    Ann Arbor, Michigan

  • 511.74.01056 Boehringer Ingelheim Investigational Site

    Bingham Farms, Michigan

  • 511.74.01010 Boehringer Ingelheim Investigational Site

    St Louis, Missouri

  • 511.74.01012 Boehringer Ingelheim Investigational Site

    Billings, Montana

  • 511.74.01045 Boehringer Ingelheim Investigational Site

    Omaha, Nebraska

  • 511.74.01041 Boehringer Ingelheim Investigational Site

    Las Vegas, Nevada

  • 511.74.01055 Boehringer Ingelheim Investigational Site

    Reno, Nevada

  • 511.74.01018 Boehringer Ingelheim Investigational Site

    Poughkeepsie, New York

  • 511.74.01011 Boehringer Ingelheim Investigational Site

    Rochester, New York

  • 511.74.01048 Boehringer Ingelheim Investigational Site

    Winston-Salem, North Carolina

  • 511.74.01021 Boehringer Ingelheim Investigational Site

    Cincinnati, Ohio

Showing 40 of 65 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.